Epi Analyzer

Text with Title

Evaluate Epi Analyzer provides unique insights on the commercial value of an indication as well as patient populations, bringing together Evaluate’s expertise in consensus forecasts with a highly granular epidemiology database.

Epi Analyzer combines a transparent and validated methodology, along with a detailed patient segmentation, giving you the tools to uncover commercial opportunities that meet targeted clinical needs across multiple regions.

Designed by expert epidemiologists, our granular coverage includes over 220 diseases and 8,000 sub-populations to give you deeper insights for better commercial decisions.

Contact Us Download brochure

Evaluate consensus forecasts integrated with Epi data in one user-friendly platform

Build robust product valuations with detailed patient segmentation covering over 220 diseases and 8,000 sub-populations and measure the true value of a product.

Perform disease profiling with a customisable interface and data sets with details on biomarkers, co-morbidities, line of therapy, disability scales, and age coverage from 0 to 100 in 5 year increments.

Contact Us
Epi Analyzer Screen Shot
Fragmented World

Identify key patient populations across markets

Quantify patient populations for clinical trial design selecting disease and conditions across 55 countries.

Conduct budget impact analysis, health economics modelling, and forecast future changes in patient populations, drivers, and its impact on sales.

Download infographic

Request more information

Evaluate is not a package I can do without... It's an absolute timesaver, and if you're saving time you're saving money.

ANTHONY M, SENIOR DIRECTOR, COMPETITIVE INTELLIGENCE & PROSPECTION, NOVARTIS

Epi Analyzer helps us understand the targets and mechanisms driving consensus forecasts, and how crowded the market may be, so we can identify development opportunities.

NATHAN D, SENIOR VP, CORPORATE DEVELOPMENT, RUBIUS THERAPEUTICS